Developing small molecules to treat infectious diseases and combat the growing threat of resistant bacterial infections

Inicure is developing patent-protected compounds acting as potent agonists of the formyl peptide receptor-1 (FPR1). Our compounds show potent anti-infective effects in preclinical infection models, including E. coli UTIs and Multi Resistant Staphylococcus Aureus (MRSA) infections, without causing toxicity.

Impact: Provides a novel tool in the battle against antibiotic resistance

CEO: Peter Olofsson-Sahl
GUV Contact: Klementina Österberg